Of note, our data showing that there is no significant difference in the frequency of SIRPα/β+memory B cells between RA patients that are responders vs. non-responders to cDMARD treatment supports that the frequency of SIRPα/β+memory B cells is related to an ADA-specific lack of response (Figure S5). This evidence concerns the gene ADA and rheumatoid arthritis.